Summary
Eli Lilly and Company (LLY) announced on February 7, 2024, its successful issuance of $6.45 billion in aggregate principal amount of senior notes through an underwriting agreement with several major financial institutions. This offering comprised five tranches of notes with varying maturities ranging from 2027 to 2064 and coupon rates from 4.500% to 5.100%. The net proceeds from this significant debt issuance, totaling approximately $6.45 billion after deducting underwriting discounts, are expected to bolster Lilly's financial flexibility. This substantial capital raise indicates Lilly's strategic approach to financing its operations, research and development, and potential future growth initiatives. The diverse maturity profile of the notes allows for a structured approach to debt management. Investors should note that the company retains the option to redeem these notes under specific conditions, and the principal amount may become immediately due and payable in the event of a default, as outlined in the indenture agreement.
Key Highlights
- 1Eli Lilly raised approximately $6.45 billion in net proceeds from the issuance of senior notes.
- 2The offering included five series of notes with aggregate principal amounts totaling $6.45 billion.
- 3Note maturities range from 2027 to 2064, with coupon rates between 4.500% and 5.100%.
- 4The issuance was facilitated through an underwriting agreement with a syndicate of prominent investment banks.
- 5The offering was registered under a Form S-3 registration statement, indicating prior SEC review.
- 6The company has the option to redeem the notes, in whole or in part, under specified terms.
- 7An Event of Default could lead to the acceleration of principal repayment for the notes.